Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE3
Study Classification
INTERVENTIONAL
Study Start Date
1984-09-30
Study Completion Date
2005-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In the Lung Health Study I, to determine the effects of Special Care, compared to Usual Care, on rate of decline in pulmonary function in a group of cigarette smokers identified as having mild abnormalities in pulmonary function.
In the Lung Health Study III, to determine the long-term effects of smoking cessation and continued smoking, on cardiopulmonary morbidity, mortality, and the rate of decline in the one second forced expiratory volume (FEV1) in men and women with early chronic obstructive lung disease who have been followed prospectively for 12 to 15 years.
In the Lung Health Study III, to determine the long-term effects of smoking cessation and continued smoking, on cardiopulmonary morbidity, mortality, and the rate of decline in the one second forced expiratory volume (FEV1) in men and women with early chronic obstructive lung disease who have been followed prospectively for 12 to 15 years.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Airway Limitation Study: Study In Primary Care Centers Of Chronic Bronchitis In Long-Term Cigarette Smokers Of At Least 40 Years Of Age With Symptoms Of Cough And Shortness Of Breath
NCT00442468
Pulmonary Disease, Chronic Obstructive
COMPLETED
Prevalence of Chronic Airway Obstruction in Subjects With a History of Cigarette Smoking in a Primary Care Setting
NCT01013948
Pulmonary Disease, Chronic Obstructive
COMPLETED
Longitudinal Study of Cortisol and Pulmonary Function
NCT00005370
Lung Diseases, Obstructive
Chronic Obstructive Pulmonary Disease
COMPLETED
Effect of Maternal Smoking On Neonatal Lung Function
NCT00005285
Lung Diseases, Obstructive
Chronic Obstructive Pulmonary Disease
COMPLETED
Determinants of Respiratory Health in Young Adults
NCT00005361
Lung Diseases
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
BACKGROUND:
Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity in the United States, affecting nearly 10 million persons. COPD accounts for 60,000 deaths yearly and ranks as the fourth leading cause of death. If current trends continue, it may become the nation's fourth or even third leading cause of death by the year 2000.
Epidemiological studies consistently indicated that smoking was the over-whelming risk factor for accelerated decline in pulmonary function and subsequent development of COPD. Furthermore, evidence from several studies indicated that the rate of decline in pulmonary function approached a more normal rate of decline upon cessation of cigarette smoking.
Another presumed risk factor for accelerated decline in pulmonary function was the presence of hyperreactive airways, although it was not clear whether the mere presence of hyperreactive airways contributed to the accelerated decline, or whether the decline resulted from the reaction of the airways to various irritants over a long period of time. It is possible that if the hyperreactive airway was kept non-reactive by pharmacological means over a period of years, the expected abnormal decline might be lessened. This effect might be enhanced by the cessation of cigarette smoking.
Although the evidence was strong that smoking and hyperreactive airways were risk factors for COPD, it had not been demonstrated whether removal of risk factors at a stage when mild dysfunction had already occurred would effectively modify the course of COPD.
DESIGN NARRATIVE:
Lung Health Study I
Randomized and controlled. Cigarette smokers with evidence of airways obstruction underwent baseline testing that included spirometric responses to isoproterenol and methacholine and were then randomly assigned to one of three groups: a no intervention or usual care group; a group receiving a smoking cessation program and bronchodilator therapy; a group receiving a smoking cessation program and a placebo bronchodilator. The placebo/bronchodilator therapy was double-blind. The smoking intervention consisted of an intensive 12-session smoking cessation program combining behavior modification and use of nicotine gum, with a continuing five-year maintenance program to minimize relapse. The bronchodilator consisted of ipratropium bromide prescribed three times daily, two puffs per time, from a metered-dose inhaler. All groups were followed yearly for five years. The primary endpoint was the rate of change of FEV1. Respiratory morbidity was a secondary endpoint. Recruitment began in November 1986 and was completed in January 1989. The clinical phase of the trial ended in April 1994. The study continues under contract N01-HR-46002 through September, 2004 for data analysis and dissemination of research results.
Lung Health Study III
Beginning in fiscal year 1998, all surviving participants of LHS I are invited to participate in the long-term followup. The study will determine, using an intent-to-treat analysis, whether the LHS I smoking intervention significantly reduces the incidence of clinically important respiratory and cardiovascular disease over a 12- to 15-year period following study enrollment. The study will also estimate the magnitude of the effects of FEV1 and FVC on the risks of cardiovascular and respiratory morbidity and mortality, after controlling for smoking history. Studies will be conducted on the role of other factors such as gender, airways reactivity, weight gain, and co-morbidities in determining the rate of decline in pulmonary function and the risks of cardiovascular and respiratory morbidity and mortality. A determination will also be made as to whether the improvement in lung function and reduction in respiratory symptoms associated with smoking cessation result in improved health-related quality of life (HRQL) and less depression over an extended follow-up period. The LHS III, an investigator initiated long-term follow-up study, is not an NIH- defined clinical trial.
Chronic obstructive pulmonary disease (COPD) is a major cause of mortality and morbidity in the United States, affecting nearly 10 million persons. COPD accounts for 60,000 deaths yearly and ranks as the fourth leading cause of death. If current trends continue, it may become the nation's fourth or even third leading cause of death by the year 2000.
Epidemiological studies consistently indicated that smoking was the over-whelming risk factor for accelerated decline in pulmonary function and subsequent development of COPD. Furthermore, evidence from several studies indicated that the rate of decline in pulmonary function approached a more normal rate of decline upon cessation of cigarette smoking.
Another presumed risk factor for accelerated decline in pulmonary function was the presence of hyperreactive airways, although it was not clear whether the mere presence of hyperreactive airways contributed to the accelerated decline, or whether the decline resulted from the reaction of the airways to various irritants over a long period of time. It is possible that if the hyperreactive airway was kept non-reactive by pharmacological means over a period of years, the expected abnormal decline might be lessened. This effect might be enhanced by the cessation of cigarette smoking.
Although the evidence was strong that smoking and hyperreactive airways were risk factors for COPD, it had not been demonstrated whether removal of risk factors at a stage when mild dysfunction had already occurred would effectively modify the course of COPD.
DESIGN NARRATIVE:
Lung Health Study I
Randomized and controlled. Cigarette smokers with evidence of airways obstruction underwent baseline testing that included spirometric responses to isoproterenol and methacholine and were then randomly assigned to one of three groups: a no intervention or usual care group; a group receiving a smoking cessation program and bronchodilator therapy; a group receiving a smoking cessation program and a placebo bronchodilator. The placebo/bronchodilator therapy was double-blind. The smoking intervention consisted of an intensive 12-session smoking cessation program combining behavior modification and use of nicotine gum, with a continuing five-year maintenance program to minimize relapse. The bronchodilator consisted of ipratropium bromide prescribed three times daily, two puffs per time, from a metered-dose inhaler. All groups were followed yearly for five years. The primary endpoint was the rate of change of FEV1. Respiratory morbidity was a secondary endpoint. Recruitment began in November 1986 and was completed in January 1989. The clinical phase of the trial ended in April 1994. The study continues under contract N01-HR-46002 through September, 2004 for data analysis and dissemination of research results.
Lung Health Study III
Beginning in fiscal year 1998, all surviving participants of LHS I are invited to participate in the long-term followup. The study will determine, using an intent-to-treat analysis, whether the LHS I smoking intervention significantly reduces the incidence of clinically important respiratory and cardiovascular disease over a 12- to 15-year period following study enrollment. The study will also estimate the magnitude of the effects of FEV1 and FVC on the risks of cardiovascular and respiratory morbidity and mortality, after controlling for smoking history. Studies will be conducted on the role of other factors such as gender, airways reactivity, weight gain, and co-morbidities in determining the rate of decline in pulmonary function and the risks of cardiovascular and respiratory morbidity and mortality. A determination will also be made as to whether the improvement in lung function and reduction in respiratory symptoms associated with smoking cessation result in improved health-related quality of life (HRQL) and less depression over an extended follow-up period. The LHS III, an investigator initiated long-term follow-up study, is not an NIH- defined clinical trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Lung Diseases
Lung Diseases, Obstructive
Chronic Obstructive Pulmonary Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Primary Study Purpose
PREVENTION
Blinding Strategy
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
smoking cessation
Intervention Type
BEHAVIORAL
ipratropium
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Men and women who were cigarette smokers and between the ages of 35 and 60.
Minimum Eligible Age
35 Years
Maximum Eligible Age
60 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Sponsor Role
lead
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
John Connett
Role:
University of Minnesota
References
Explore related publications, articles, or registry entries linked to this study.
Durkin DA, Kjelsberg MO, Buist AS, Connett JE, Owens GR. Recruitment of participants in the Lung Health Study, I: Description of methods. Control Clin Trials. 1993 Apr;14(2 Suppl):20S-37S. doi: 10.1016/0197-2456(93)90022-6.
Reference Type
BACKGROUND
Lung Health Study Research Group: The Lung Health Study: Introduction. Controlled Clin Trials, 14(2):1S-2S, 1993.
Reference Type
BACKGROUND
Connett JE, Kusek JW, Bailey WC, O'Hara P, Wu M. Design of the Lung Health Study: a randomized clinical trial of early intervention for chronic obstructive pulmonary disease. Control Clin Trials. 1993 Apr;14(2 Suppl):3S-19S. doi: 10.1016/0197-2456(93)90021-5.
Reference Type
BACKGROUND
Connett JE, Bjornson-Benson WM, Daniels K. Recruitment of participants in the Lung Health Study, II: Assessment of recruiting strategies. Control Clin Trials. 1993 Apr;14(2 Suppl):38S-51S. doi: 10.1016/0197-2456(93)90023-7.
Reference Type
BACKGROUND
Bjornson-Benson WM, Stibolt TB, Manske KA, Zavela KJ, Youtsey DJ, Buist AS. Monitoring recruitment effectiveness and cost in a clinical trial. Control Clin Trials. 1993 Apr;14(2 Suppl):52S-67S. doi: 10.1016/0197-2456(93)90024-8.
Reference Type
BACKGROUND
Rudick C, Anthonisen NR, Manfreda J. Recruiting healthy participants for a large clinical trial. Control Clin Trials. 1993 Apr;14(2 Suppl):68S-79S. doi: 10.1016/0197-2456(93)90025-9.
Reference Type
BACKGROUND
Hurd SS. Lung Health Study: pulmonary function testing. Am Rev Respir Dis. 1991 Jun;143(6):1211. doi: 10.1164/ajrccm/143.6.1211. No abstract available.
Reference Type
BACKGROUND
Tashkin DP, Altose MD, Bleecker ER, Connett JE, Kanner RE, Lee WW, Wise R. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am Rev Respir Dis. 1992 Feb;145(2 Pt 1):301-10. doi: 10.1164/ajrccm/145.2_Pt_1.301.
Reference Type
BACKGROUND
Bjornson-Benson W, Nides M, Dolce J, Rand C, Lindgren P, O'Hara P, Buist AS. Nicotine gum use in the first year of the Lung Health Study. Addict Behav. 1993 Jul-Aug;18(4):491-502. doi: 10.1016/0306-4603(93)90066-i.
Reference Type
BACKGROUND
Buist AS, Connett JE, Miller RD, Kanner RE, Owens GR, Voelker HT. Chronic Obstructive Pulmonary Disease Early Intervention Trial (Lung Health Study). Baseline characteristics of randomized participants. Chest. 1993 Jun;103(6):1863-72. doi: 10.1378/chest.103.6.1863.
Reference Type
BACKGROUND
Buist AS, Connett JE. The Lung Health Study. Baseline characteristics of randomized participants. Chest. 1993 Jun;103(6):1644. doi: 10.1378/chest.103.6.1644a. No abstract available.
Reference Type
BACKGROUND
Istvan JA, Nides MA, Buist AS, Greene P, Voelker H. Salivary cotinine, frequency of cigarette smoking, and body mass index: findings at baseline in the Lung Health Study. Am J Epidemiol. 1994 Mar 15;139(6):628-36. doi: 10.1093/oxfordjournals.aje.a117052.
Reference Type
BACKGROUND
Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O'Hara P, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994 Nov 16;272(19):1497-505.
Reference Type
BACKGROUND
Gross NJ. The lung health study. Disappointment and triumph. JAMA. 1994 Nov 16;272(19):1539-41. No abstract available.
Reference Type
BACKGROUND
Enright PL, Johnson LR, Connett JE, Voelker H, Buist AS. Spirometry in the Lung Health Study. 1. Methods and quality control. Am Rev Respir Dis. 1991 Jun;143(6):1215-23. doi: 10.1164/ajrccm/143.6.1215.
Reference Type
BACKGROUND
Kanner RE, Connett JE, Altose MD, Buist AS, Lee WW, Tashkin DP, Wise RA. Gender difference in airway hyperresponsiveness in smokers with mild COPD. The Lung Health Study. Am J Respir Crit Care Med. 1994 Oct;150(4):956-61. doi: 10.1164/ajrccm.150.4.7921469.
Reference Type
BACKGROUND
Murray RP, Connett JE, Lauger GG, Voelker HT. Error in smoking measures: effects of intervention on relations of cotinine and carbon monoxide to self-reported smoking. The Lung Health Study Research Group. Am J Public Health. 1993 Sep;83(9):1251-7. doi: 10.2105/ajph.83.9.1251.
Reference Type
BACKGROUND
O'Hara P, Grill J, Rigdon MA, Connett JE, Lauger GA, Johnston JJ. Design and results of the initial intervention program for the Lung Health Study. The Lung Health Study Research Group. Prev Med. 1993 May;22(3):304-15. doi: 10.1006/pmed.1993.1025.
Reference Type
BACKGROUND
Nides MA, Rakos RF, Gonzales D, Murray RP, Tashkin DP, Bjornson-Benson WM, Lindgren P, Connett JE. Predictors of initial smoking cessation and relapse through the first 2 years of the Lung Health Study. J Consult Clin Psychol. 1995 Feb;63(1):60-9. doi: 10.1037//0022-006x.63.1.60.
Reference Type
BACKGROUND
Bjornson W, Rand C, Connett JE, Lindgren P, Nides M, Pope F, Buist AS, Hoppe-Ryan C, O'Hara P. Gender differences in smoking cessation after 3 years in the Lung Health Study. Am J Public Health. 1995 Feb;85(2):223-30. doi: 10.2105/ajph.85.2.223.
Reference Type
BACKGROUND
Enright PL, Connett JE, Kanner RE, Johnson LR, Lee WW. Spirometry in the Lung Health Study: II. Determinants of short-term intraindividual variability. Am J Respir Crit Care Med. 1995 Feb;151(2 Pt 1):406-11. doi: 10.1164/ajrccm.151.2.7842199.
Reference Type
BACKGROUND
Wise RA, Connett J, Kurnow K, Grill J, Johnson L, Kanner R, Enright P. Selection of spirometric measurements in a clinical trial, the Lung Health Study. Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 1):675-81. doi: 10.1164/ajrccm.151.3.7881655.
Reference Type
BACKGROUND
Nides M, Rand C, Dolce J, Murray R, O'Hara P, Voelker H, Connett J. Weight gain as a function of smoking cessation and 2-mg nicotine gum use among middle-aged smokers with mild lung impairment in the first 2 years of the Lung Health Study. Health Psychol. 1994 Jul;13(4):354-61. doi: 10.1037//0278-6133.13.4.354.
Reference Type
BACKGROUND
Owens GR: Lung Health Study: Assessing the Impact of Early Intervention. Monograph. Chronic Bronchitis: Time to Act, Strategies for Prevention and Intervention. From the Proceedings of the Boehringer Ingelheim Ireland Symposium. Killarney, Ireland, July 1988.
Reference Type
BACKGROUND
Connett JE, Lee WW. Estimation of the coefficient of variation from laboratory analysis of split specimens for quality control in clinical trials. Control Clin Trials. 1990 Feb;11(1):24-36. doi: 10.1016/0197-2456(90)90029-2.
Reference Type
BACKGROUND
Owens GR: Pulmonary Function Tests as Guides in the Differential Physiologic Comparisons of Obstructive Pulmonary Diseases. J Respir Dis, II(6):S23-S29, 1990.
Reference Type
BACKGROUND
Tashkin DP, Rand C, Nides M, Simmons M, Wise R, Coulson AH, Li V, Gong H Jr. A nebulizer chronolog to monitor compliance with inhaler use. Am J Med. 1991 Oct 21;91(4A):33S-36S. doi: 10.1016/0002-9343(91)90260-5.
Reference Type
BACKGROUND
Owens GR. Public screening for lung disease: experience with the NIH Lung Health Study. Am J Med. 1991 Oct 21;91(4A):37S-40S. doi: 10.1016/0002-9343(91)90261-u.
Reference Type
BACKGROUND
Rand CS, Wise RA, Nides M, Simmons MS, Bleecker ER, Kusek JW, Li VC, Tashkin DP. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis. 1992 Dec;146(6):1559-64. doi: 10.1164/ajrccm/146.6.1559.
Reference Type
BACKGROUND
Nides MA, Tashkin DP, Simmons MS, Wise RA, Li VC, Rand CS. Improving inhaler adherence in a clinical trial through the use of the nebulizer chronolog. Chest. 1993 Aug;104(2):501-7. doi: 10.1378/chest.104.2.501.
Reference Type
BACKGROUND
Wu MC, Lan KK, Connett JE. Use of surrogate information time for monitoring the effect of treatment on the change in a response variable in clinical trials. Stat Med. 1994 May 15;13(9):945-53. doi: 10.1002/sim.4780130905.
Reference Type
BACKGROUND
Johnson LR, Enright PL, Voelker HT, Tashkin DP. Volume spirometers need automated internal temperature sensors. Am J Respir Crit Care Med. 1994 Dec;150(6 Pt 1):1575-80. doi: 10.1164/ajrccm.150.6.7952617.
Reference Type
BACKGROUND
Istvan JA, Buist AS, Hess DL, Voelker H. Relationship of smoking cessation and nicotine gum use to salivary androstenedione and testosterone in middle-aged men. Metabolism. 1995 Jan;44(1):90-5. doi: 10.1016/0026-0495(95)90294-5.
Reference Type
BACKGROUND
Murray RP, Istvan JA, Voelker HT, Rigdon MA, Wallace MD. Level of involvement with alcohol and success at smoking cessation in the lung health study. J Stud Alcohol. 1995 Jan;56(1):74-82. doi: 10.15288/jsa.1995.56.74.
Reference Type
BACKGROUND
Tashkin DP, Altose MD, Connett JE, et al and the Lung Health Study Research Group: Airway Hyperresponsiveness in "Irreversible" Chronic Obstructive Pulmonary Disease. In: Spector SL, (Ed). Provocation Testing in Clinical Practice. New York, Marcel Dekker, Inc. ,575-598, 1995.
Reference Type
BACKGROUND
Murray RP, Johnston JJ, Dolce JJ, Lee WW, O'Hara P. Social support for smoking cessation and abstinence: the Lung Health Study. Lung Health Study Research Group. Addict Behav. 1995 Mar-Apr;20(2):159-70. doi: 10.1016/s0306-4603(99)80001-x.
Reference Type
BACKGROUND
Murray RP, Bailey WC, Daniels K, Bjornson WM, Kurnow K, Connett JE, Nides MA, Kiley JP. Safety of nicotine polacrilex gum used by 3,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest. 1996 Feb;109(2):438-45. doi: 10.1378/chest.109.2.438.
Reference Type
BACKGROUND
Pope CA 3rd, Kanner RE. Acute effects of PM10 pollution on pulmonary function of smokers with mild to moderate chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993 Jun;147(6 Pt 1):1336-40. doi: 10.1164/ajrccm/147.6_Pt_1.1336.
Reference Type
BACKGROUND
Utell MJ, Samet JM. Particulate air pollution and health. New evidence on an old problem. Am Rev Respir Dis. 1993 Jun;147(6 Pt 1):1334-5. doi: 10.1164/ajrccm/147.6_Pt_1.1334. No abstract available.
Reference Type
BACKGROUND
Owens G. Editorial: Obstructive, Occupational, and Environmental Diseases: Editorial Overview. Current Opinion in Pul Med, 1:73-75, 1995.
Reference Type
BACKGROUND
Istvan J, Murray R, Voelker H. The relationship between patterns of alcohol consumption and body weight. Lung Health Study Research Group. Int J Epidemiol. 1995 Jun;24(3):543-6. doi: 10.1093/ije/24.3.543.
Reference Type
BACKGROUND
Rand CS, Nides M, Cowles MK, Wise RA, Connett J. Long-term metered-dose inhaler adherence in a clinical trial. The Lung Health Study Research Group. Am J Respir Crit Care Med. 1995 Aug;152(2):580-8. doi: 10.1164/ajrccm.152.2.7633711.
Reference Type
BACKGROUND
Murray RP, Istvan JA, Voelker HT. Does cessation of smoking cause a change in alcohol consumption? Evidence from the Lung Health Study. Subst Use Misuse. 1996 Jan;31(2):141-56. doi: 10.3109/10826089609045804.
Reference Type
BACKGROUND
Cowles MK, Carlin BP, Conett JE: Bayesian Tobit Modeling of Longitudinal Ordinal Clinical Trial Compliance Data with Nonignorable Missingness. J Am Stat Assoc, 92(433):86-98, 1996.
Reference Type
BACKGROUND
Simmons MS, Nides MA, Rand CS, Wise RA, Tashkin DP. Trends in compliance with bronchodilator inhaler use between follow-up visits in a clinical trial. Chest. 1996 Apr;109(4):963-8. doi: 10.1378/chest.109.4.963.
Reference Type
BACKGROUND
Kanner RE. Early intervention in chronic obstructive pulmonary disease. A review of the Lung Health Study results. Med Clin North Am. 1996 May;80(3):523-47. doi: 10.1016/s0025-7125(05)70452-1.
Reference Type
BACKGROUND
Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA. Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1802-11. doi: 10.1164/ajrccm.153.6.8665038.
Reference Type
BACKGROUND
Murray RP, Voelker HT, Rakos RF, Nides MA, McCutcheon VJ, Bjornson W. Intervention for relapse to smoking: the Lung Health Study restart programs. Addict Behav. 1997 Mar-Apr;22(2):281-6. doi: 10.1016/s0306-4603(96)00008-1.
Reference Type
BACKGROUND
Bjornson W: Early Chronic Obstructive Pulmonary Disease: Results from the Lung Health Study. Am J Health Behav, 20(5):270-278, 1996.
Reference Type
BACKGROUND
Wise RA, Enright PL, Connett JE, Anthonisen NR, Kanner RE, Lindgren P, O'Hara P, Owens GR, Rand CS, Tashkin DP. Effect of weight gain on pulmonary function after smoking cessation in the Lung Health Study. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 1):866-72. doi: 10.1164/ajrccm.157.3.9706076.
Reference Type
BACKGROUND
Murray RP, Istvan JA, Daniels K, Beaudoin CM. Alcohol and morbidity in the Lung Health Study. J Stud Alcohol. 1998 May;59(3):250-7. doi: 10.15288/jsa.1998.59.250.
Reference Type
BACKGROUND
O'Hara P, Connett JE, Lee WW, Nides M, Murray R, Wise R. Early and late weight gain following smoking cessation in the Lung Health Study. Am J Epidemiol. 1998 Nov 1;148(9):821-30. doi: 10.1093/oxfordjournals.aje.a009706.
Reference Type
BACKGROUND
Thun MJ, Colditz GA. Invited commentary on "early and late weight gain following smoking cessation in the Lung Health Study". Am J Epidemiol. 1998 Nov 1;148(9):831-2. doi: 10.1093/oxfordjournals.aje.a009707. No abstract available.
Reference Type
BACKGROUND
Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS, Tashkin DP; Lung Health Study Research Group. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med. 2000 Feb;161(2 Pt 1):381-90. doi: 10.1164/ajrccm.161.2.9901044.
Reference Type
BACKGROUND
Istvan JA, Lee WW, Buist AS, Connett JE. Relation of salivary cotinine to blood pressure in middle-aged cigarette smokers. Am Heart J. 1999 May;137(5):928-31. doi: 10.1016/s0002-8703(99)70418-7.
Reference Type
BACKGROUND
Kanner RE, Connett JE, Williams DE, Buist AS. Effects of randomized assignment to a smoking cessation intervention and changes in smoking habits on respiratory symptoms in smokers with early chronic obstructive pulmonary disease: the Lung Health Study. Am J Med. 1999 Apr;106(4):410-6. doi: 10.1016/s0002-9343(99)00056-x.
Reference Type
BACKGROUND
Sandford AJ, Chagani T, Weir TD, Connett JE, Anthonisen NR, Pare PD. Susceptibility genes for rapid decline of lung function in the lung health study. Am J Respir Crit Care Med. 2001 Feb;163(2):469-73. doi: 10.1164/ajrccm.163.2.2006158.
Reference Type
BACKGROUND
Kanner RE, Anthonisen NR, Connett JE; Lung Health Study Research Group. Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med. 2001 Aug 1;164(3):358-64. doi: 10.1164/ajrccm.164.3.2010017.
Reference Type
BACKGROUND
Murray RP, Connett JE, Buist AS, Gerald LB, Eichenhorn MS. Experience of Black participants in the Lung Health Study smoking cessation intervention program. Nicotine Tob Res. 2001 Nov;3(4):375-82. doi: 10.1080/14622200110081435.
Reference Type
BACKGROUND
Murray RP, Gerald LB, Lindgren PG, Connett JE, Rand CS, Anthonisen NR. Characteristics of participants who stop smoking and sustain abstinence for 1 and 5 years in the Lung Health Study. Prev Med. 2000 May;30(5):392-400. doi: 10.1006/pmed.2000.0642.
Reference Type
BACKGROUND
Anthonisen NR, Connett JE, Enright PL, Manfreda J; Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002 Aug 1;166(3):333-9. doi: 10.1164/rccm.2110093.
Reference Type
BACKGROUND
Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med. 2002 Sep 1;166(5):675-9. doi: 10.1164/rccm.2112096.
Reference Type
BACKGROUND
Connett JE, Murray RP, Buist AS, Wise RA, Bailey WC, Lindgren PG, Owens GR; Lung Health Study Research Group. Changes in smoking status affect women more than men: results of the Lung Health Study. Am J Epidemiol. 2003 Jun 1;157(11):973-9. doi: 10.1093/aje/kwg083.
Reference Type
BACKGROUND
Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE; Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005 Feb 15;142(4):233-9. doi: 10.7326/0003-4819-142-4-200502150-00005.
Reference Type
BACKGROUND
Samet JM. Smoking kills: experimental proof from the Lung Health Study. Ann Intern Med. 2005 Feb 15;142(4):299-301. doi: 10.7326/0003-4819-142-4-200502150-00012. No abstract available.
Reference Type
BACKGROUND
Murray RP, Anthonisen NR, Connett JE, Wise RA, Lindgren PG, Greene PG, Nides MA. Effects of multiple attempts to quit smoking and relapses to smoking on pulmonary function. Lung Health Study Research Group. J Clin Epidemiol. 1998 Dec;51(12):1317-26. doi: 10.1016/s0895-4356(98)00120-6.
Reference Type
BACKGROUND
Murray RP, Nides MA, Istvan JA, Daniels K. Levels of cotinine associated with long-term ad-libitum nicotine polacrilex use in a clinical trial. Addict Behav. 1998 Jul-Aug;23(4):529-35. doi: 10.1016/s0306-4603(97)00073-7.
Reference Type
BACKGROUND
Anthonisen NR. Lung Health Study. Am Rev Respir Dis. 1989 Oct;140(4):871-2. doi: 10.1164/ajrccm/140.4.871. No abstract available.
Reference Type
BACKGROUND
Obeidat M, Zhou G, Li X, Hansel NN, Rafaels N, Mathias R, Ruczinski I, Beaty TH, Barnes KC, Pare PD, Sin DD. The genetics of smoking in individuals with chronic obstructive pulmonary disease. Respir Res. 2018 Apr 10;19(1):59. doi: 10.1186/s12931-018-0762-7.
Reference Type
DERIVED
Zafari Z, Sin DD, Postma DS, Lofdahl CG, Vonk J, Bryan S, Lam S, Tammemagi CM, Khakban R, Man SFP, Tashkin D, Wise RA, Connett JE, McManus B, Ng R, Hollander Z, Sadatsafavi M. Individualized prediction of lung-function decline in chronic obstructive pulmonary disease. CMAJ. 2016 Oct 4;188(14):1004-1011. doi: 10.1503/cmaj.151483. Epub 2016 Aug 2.
Reference Type
DERIVED
Sze MA, Chen YW, Tam S, Tashkin D, Wise RA, Connett JE, Man SP, Sin DD. The relationship between Helicobacter pylori seropositivity and COPD. Thorax. 2015 Oct;70(10):923-9. doi: 10.1136/thoraxjnl-2015-207059. Epub 2015 May 29.
Reference Type
DERIVED
Study Documents
Access uploaded study-related documents such as protocols, statistical analysis plans, or lay summaries.
Document Type: Individual Participant Data Set
NHLBI provides controlled access to IPD through BioLINCC. Access requires registration, evidence of local IRB approval or certification of exemption from IRB review, and completion of a data use agreement.
View DocumentOther Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
206
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Evaluation of the Causes and Disease Processes of Chronic Lung Disease
NCT00001183
COMPLETED
Lung Health of Early COPD: A Multi-center Cohort Study
NCT05466396
RECRUITING
A Study Into Airways Disease Case Finding and Management
NCT03355677
COMPLETED
NA
Pulmonary Function Changes in 10 Pack Year Smokers With Chronic Bronchitis
NCT00454675
COMPLETED
Effects of Smoking on Bronchial Epithelium
NCT00849433
COMPLETED
How Smoking Causes COPD: Examination of Immune System Changes
NCT00186719
UNKNOWN
Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals
NCT00001462
COMPLETED
Tucson Epidemiology Study of Chronic Obstructive Lung Diseases
NCT00005279
COMPLETED
Early Risk Predictors For Chronic Pulmonary Disease
NCT00005281
COMPLETED
A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period
NCT03261037
COMPLETED
NA
Genomic/ Proteomic/ Metabonomic Profiling in Chronic Obstructive Pulmonary Disease (COPD)
NCT00655694
WITHDRAWN
AI in PRImary Care Spirometry Pathways for Diagnosis of Lung Disease (APRIL)
NCT05865249
ACTIVE_NOT_RECRUITING
NA
Cigarette Smoke Nasal and Whole Blood Challenge in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT00159341
COMPLETED
PHASE1
American Lung Association (ALA) Lung Health Cohort
NCT04543461
RECRUITING
Diet and Chronic Obstructive Pulmonary Disease
NCT00006419
COMPLETED
Impact of Current Smoking in the Tolerance of Bronchoscopy
NCT01345383
TERMINATED
Pulmonaryhypertension in Copd at Different Levels of Smoking
NCT06031311
UNKNOWN
It's Not JUST Idiopathic Pulmonary Fibrosis Study
NCT03670576
UNKNOWN
A Study in People With Pulmonary Fibrosis to Monitor Cough With a Wearable Device
NCT05670587
COMPLETED
NA
Blood Fibrocytes During an Exacerbation and Lung Function Decline in Patients With COPD in Primary Care.
NCT04005833
TERMINATED
Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
NCT02055222
COMPLETED
Prospective Evaluation of Adult Pulmonary Langerhans Cell Histiocytosis
NCT01225601
COMPLETED
Obesity, Metabolic Dysregulation and the Airway Epithelium in Asthmatics
NCT03215836
RECRUITING
NA
Identifying Early Chronic Obstructive Pulmonary Disease (COPD) Using Health Administrative Data
NCT04966637
COMPLETED
Change in Airway Peripheral Tone in COPD
NCT04166812
UNKNOWN